IMUX Immunic: Forward P/S Multiple
Analyzing the forward P/S trend in GURU.Markets reveals how small molecule patents protect Immunic, Inc. (IMUX) positions against injectable drugs. The convenience of tablets for psoriasis and sclerosis therapy accelerates business expansion, while determines the current status of the parameter. Anticipation of Phase 2 trial results serves as a powerful driver for the company's valuation growth.
Metric breakdowns and analytics for immunic-therapeutics.com (IMUX)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
IMUX - Final Profit|Projected Future Earnings Immunic, Inc.|IMUX - Business Payback Period|Future Price to Earnings Immunic|IMUX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple IMUX|IMUX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Immunic|IMUX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth immunic-therapeutics.com|IMUX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Immunic, Inc.
- sales and revenue data:
Fundamental company valuation:Immunic Inc IMUX
For Immunic, Inc. (IMUX), the forward P/S reflects market expectations for the future monetization of immunological developments, correlating current capitalization with projected sales volume. The trend of the forward P/S valuation is based on a daily recalculation of consensus revenue forecasts, accounting for the high readiness of contract manufacturing capacities to release drugs, which allows investors to promptly assess the asset's degree of overbought status relative to its potential.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple immunovant.com|Price-to-Projected Revenue Ratio Kiniksa|Forward Price-to-Revenue Multiple Grifols SA (GRFS)|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX: Market Cap to Projected Revenue|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|PHVS: Forward P/S Multiple|Forward Price-to-Revenue Multiple AbCellera Corp|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO: Market Cap to Projected Revenue|Immunome, Inc. - Forward P/S Multiple|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|SEPN - Market Cap to Expected Sales Ratio|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple enGene Holdings Inc ENGN|RAPT: Forward Price-to-Revenue Multiple|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Market Cap to Expected Sales Ratio equilliumbio.com|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|ATRA - Forward Price-to-Revenue Multiple|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Forward Price-to-Revenue Multiple CARM|Forward P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Market Cap to Expected Sales Ratio AIM ImmunoTech, Inc. (AIM)|Aditxt Corp - Forward P/S Multiple|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|calcimedica.com - Market Cap to Projected Revenue|Forward P/S Multiple AFMD (Affimed N.V.)|ALLK - Forward Price-to-Revenue Multiple|HOOK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
